Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: Results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up

M. Wirth; C. Tyrrell; K. Delaere; M. Sánchez-Chapado; J. Ramon; D. M.A. Wallace; J. Hetherington; F. Pina; C. F. Heyns; S. Navani; J. Armstrong

doi:10.1038/sj.pcan.4500916

Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: Results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up

M. Wirth^*, C. Tyrrell, K. Delaere, M. Sánchez-Chapado, J. Ramon, D. M.A. Wallace, J. Hetherington, F. Pina, C. F. Heyns, S. Navani, J. Armstrong

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

Trial 24, one of three ongoing trials in the Early Prostate Cancer programme, is evaluating the efficacy and tolerability of bicalutamide (Casodex) 150 mg following standard care (radiotherapy, radical prostatectomy or watchful waiting) in patients with early, non-metastatic prostate cancer. At 7 years' median follow-up, addition of bicalutamide significantly improved objective progression-free survival (PFS) for patients with locally advanced disease, reducing the risk of progression by 34% versus standard care alone (hazard ratio 0.66; 95% confidence interval 0.55, 0.79; P<0.001). In localized disease, a significant difference in objective PFS was not found. There was no significant difference in overall survival.

Original language	English
Pages (from-to)	87-93
Number of pages	7
Journal	Prostate Cancer and Prostatic Diseases
Volume	10
Issue number	1
DOIs	https://doi.org/10.1038/sj.pcan.4500916
State	Published - Mar 2007
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/sj.pcan.4500916

Cite this

Wirth, M., Tyrrell, C., Delaere, K., Sánchez-Chapado, M., Ramon, J., Wallace, D. M. A., Hetherington, J., Pina, F., Heyns, C. F., Navani, S., & Armstrong, J. (2007). Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: Results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up. Prostate Cancer and Prostatic Diseases, 10(1), 87-93. https://doi.org/10.1038/sj.pcan.4500916

@article{646e44a60af244498002cb48ff89a688,

title = "Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: Results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up",

abstract = "Trial 24, one of three ongoing trials in the Early Prostate Cancer programme, is evaluating the efficacy and tolerability of bicalutamide (Casodex) 150 mg following standard care (radiotherapy, radical prostatectomy or watchful waiting) in patients with early, non-metastatic prostate cancer. At 7 years' median follow-up, addition of bicalutamide significantly improved objective progression-free survival (PFS) for patients with locally advanced disease, reducing the risk of progression by 34% versus standard care alone (hazard ratio 0.66; 95% confidence interval 0.55, 0.79; P<0.001). In localized disease, a significant difference in objective PFS was not found. There was no significant difference in overall survival.",

author = "M. Wirth and C. Tyrrell and K. Delaere and M. S{\'a}nchez-Chapado and J. Ramon and Wallace, {D. M.A.} and J. Hetherington and F. Pina and Heyns, {C. F.} and S. Navani and J. Armstrong",

year = "2007",

month = mar,

doi = "10.1038/sj.pcan.4500916",

language = "אנגלית",

volume = "10",

pages = "87--93",

journal = "Prostate Cancer and Prostatic Diseases",

issn = "1365-7852",

publisher = "Springer Nature",

number = "1",

}

Wirth, M, Tyrrell, C, Delaere, K, Sánchez-Chapado, M, Ramon, J, Wallace, DMA, Hetherington, J, Pina, F, Heyns, CF, Navani, S & Armstrong, J 2007, 'Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: Results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up', Prostate Cancer and Prostatic Diseases, vol. 10, no. 1, pp. 87-93. https://doi.org/10.1038/sj.pcan.4500916

TY - JOUR

T1 - Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer

T2 - Results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up

AU - Wirth, M.

AU - Tyrrell, C.

AU - Delaere, K.

AU - Sánchez-Chapado, M.

AU - Ramon, J.

AU - Wallace, D. M.A.

AU - Hetherington, J.

AU - Pina, F.

AU - Heyns, C. F.

AU - Navani, S.

AU - Armstrong, J.

PY - 2007/3

Y1 - 2007/3

N2 - Trial 24, one of three ongoing trials in the Early Prostate Cancer programme, is evaluating the efficacy and tolerability of bicalutamide (Casodex) 150 mg following standard care (radiotherapy, radical prostatectomy or watchful waiting) in patients with early, non-metastatic prostate cancer. At 7 years' median follow-up, addition of bicalutamide significantly improved objective progression-free survival (PFS) for patients with locally advanced disease, reducing the risk of progression by 34% versus standard care alone (hazard ratio 0.66; 95% confidence interval 0.55, 0.79; P<0.001). In localized disease, a significant difference in objective PFS was not found. There was no significant difference in overall survival.

AB - Trial 24, one of three ongoing trials in the Early Prostate Cancer programme, is evaluating the efficacy and tolerability of bicalutamide (Casodex) 150 mg following standard care (radiotherapy, radical prostatectomy or watchful waiting) in patients with early, non-metastatic prostate cancer. At 7 years' median follow-up, addition of bicalutamide significantly improved objective progression-free survival (PFS) for patients with locally advanced disease, reducing the risk of progression by 34% versus standard care alone (hazard ratio 0.66; 95% confidence interval 0.55, 0.79; P<0.001). In localized disease, a significant difference in objective PFS was not found. There was no significant difference in overall survival.

UR - http://www.scopus.com/inward/record.url?scp=33847609549&partnerID=8YFLogxK

U2 - 10.1038/sj.pcan.4500916

DO - 10.1038/sj.pcan.4500916

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 17102802

AN - SCOPUS:33847609549

SN - 1365-7852

VL - 10

SP - 87

EP - 93

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

IS - 1

ER -

Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: Results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this